Opus Genetics Q3 EPS Lifted by Brookline Capital Markets

Key Points

• Brookline Capital Markets raised its Q3 2026 EPS forecast for Opus Genetics to a loss of $0.15 per share from a previous loss estimate of $0.18. The firm still projects annual losses through at least FY2029.
• Analyst sentiment remains generally positive, with a MarketBeat consensus rating of “Moderate Buy” and an average price target of $10.69, despite Zacks Research downgrading the stock to “Strong Sell.”
• Opus Genetics recently beat quarterly EPS expectations, reporting a $0.14 loss versus the $0.16 consensus, but revenue of $0.76 million fell well below the $2.63 million estimate. Shares opened at $3.76, while insiders have sold approximately $7.5 million of stock over the past three months.

Opus Genetics, Inc. (NASDAQ:IRD - Free Report) - Equities research analysts at Brookline Capital Markets increased their Q3 2026 EPS estimates for shares of Opus Genetics in a report released on Monday, August 10th. Brookline Capital Markets analyst K. Raja now forecasts that the company will post earnings of ($0.15) per share for the quarter, up from their previous estimate of ($0.18). The consensus estimate for Opus Genetics' current full-year earnings is ($1.05) per share. Brookline Capital Markets also issued estimates for Opus Genetics' FY2026 earnings at ($0.87) EPS, FY2027 earnings at ($0.56) EPS, FY2028 earnings at ($0.61) EPS and FY2029 earnings at ($0.71) EPS.

Other equities analysts have also issued research reports about the company. Zacks Research lowered Opus Genetics from a "hold" rating to a "strong sell" rating in a research note on Monday, July 13th. Citigroup started coverage on shares of Opus Genetics in a report on Tuesday, April 28th. They issued an "outperform" rating for the company. Leerink Partners assumed coverage on shares of Opus Genetics in a research note on Thursday, May 21st. They set an "outperform" rating and a $10.00 target price on the stock. TD Cowen assumed coverage on Opus Genetics in a research note on Wednesday, July 29th. They issued a "buy" rating on the stock. Finally, Royal Bank Of Canada lowered their target price on Opus Genetics from $10.00 to $9.00 and set an "outperform" rating for the company in a research note on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, Opus Genetics has an average rating of "Moderate Buy" and an average price target of $10.69.

Opus Genetics Price Performance

Shares of IRD stock opened at $3.76 on Thursday. Opus Genetics has a 1-year low of $1.04 and a 1-year high of $5.81. The firm has a market cap of $310.76 million, a PE ratio of -2.79 and a beta of 0.59. The company has a 50-day moving average of $3.79 and a two-hundred day moving average of $4.15.

Opus Genetics (NASDAQ:IRD - Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.02. Opus Genetics had a negative return on equity of 338.88% and a negative net margin of 1,091.82%.The company had revenue of $0.76 million during the quarter, compared to analysts' expectations of $2.63 million.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of IRD. Occudo Quantitative Strategies LP acquired a new stake in shares of Opus Genetics during the fourth quarter worth about $25,000. Comerica Bank purchased a new position in shares of Opus Genetics in the 1st quarter valued at approximately $29,000. Virtu Financial LLC acquired a new position in shares of Opus Genetics in the fourth quarter valued at approximately $34,000. Raymond James Financial Inc. raised its stake in shares of Opus Genetics by 95.6% during the third quarter. Raymond James Financial Inc. now owns 22,508 shares of the company's stock worth $37,000 after purchasing an additional 11,000 shares during the last quarter. Finally, Johnson Investment Counsel Inc. purchased a new stake in shares of Opus Genetics during the fourth quarter worth approximately $40,000. 14.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, CEO George Magrath sold 9,475 shares of Opus Genetics stock in a transaction dated Thursday, July 23rd. The stock was sold at an average price of $2.95, for a total transaction of $27,951.25. Following the sale, the chief executive officer owned 1,731,869 shares in the company, valued at approximately $5,109,013.55. The trade was a 0.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Fighting Blindness Foundation sold 1,700,000 shares of the company's stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $4.35, for a total value of $7,395,000.00. Following the completion of the sale, the director directly owned 3,792,171 shares of the company's stock, valued at approximately $16,495,943.85. This trade represents a 30.95% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 1,729,331 shares of company stock worth $7,481,629. 11.70% of the stock is owned by corporate insiders.

Key Opus Genetics News

Here are the key news stories impacting Opus Genetics this week:

• Positive Sentiment: HC Wainwright raised its FY2026 EPS forecast to a loss of $1.03 from $1.18 and its FY2027 forecast to a loss of $0.40 from $0.46. The firm also projects a smaller Q4 2026 loss of $0.09, followed by profitability in FY2029 and $0.27 EPS in FY2030. HC Wainwright maintained a Buy rating and an $8.00 price target, well above the stock’s recent trading level.
• Positive Sentiment: Brookline Capital Markets expects Opus Genetics to generate $0.62 EPS in FY2030, indicating potentially stronger long-term earnings power than HC Wainwright’s estimate.
• Neutral Sentiment: Reported short interest was listed at zero shares, with a zero-day days-to-cover ratio. Because the report also showed an invalid percentage change, the data provides little meaningful indication of short-selling pressure.
• Negative Sentiment: Despite the improved forecasts, Opus Genetics is still expected to post substantial losses through FY2028, while the company’s current-year consensus estimate remains a loss of $1.09 per share. The lack of immediate earnings or revenue improvement may be limiting investor enthusiasm.

Opus Genetics Company Profile

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source